Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a 200,000 dalton EBV membrane antigen.

Abstract

In raising murine hybridoma antibodies against Epstein-Barr virus (EBV)-induced membrane antigens (MA), we found one antibody that blocked the release of infectious EBV from cultured P3HR-1 cells. This monoclonal antibody (mAb) recognized a 200 kD, phosphonoacetic acid-sensitive (late) MA, and did not directly neutralize virus without complement. When this mAb was added to 33 degrees C-cultured, spontaneously EBV-producing P3HR-1 cells, the intracellular expression of viral capsid antigen and infectious virus was not inhibited, but the appearance of infectious virus in the culture medium was significantly reduced. The duration of this suppression was dependent upon the concentration of the mAb, an effect being observed to a 1:4 X 10(5) titer of the ascites mAb preparation. A more acute effect of suppression of EBV release was observed in a second model of 12-o-tetradecanoyl phorbol-13-acetate and n-butyrate induction of EBV in 37 degrees C-cultured P3HR-1 cells. Again, intracellular infectious virus production was not inhibited, but the level of infectious virus in the culture medium was significantly reduced as early as 1 and 2 d of culture with antibody. This effect was reversed within 31 h after replacement of mAb-containing medium with fresh medium. This description of antibody-mediated inhibition of EBV release might lead to the characterization of another form of immune defense for the control of EBV infections.

Reactivation of persistent Epstein–Barr virus (EBV) causes secretion of thyrotropin receptor antibodies (TRAbs) in EBV-infected B lymphocytes with TRAbs on their surface

“…We used the culture at 33 C to induce EBV reactivation [13][14][15], although the most common inducer is phorbol ester.…”

“…In these flow cytometric analyses, we used the antibody called 72A1 against EBV gp350/220, a late antigen of EBV reactivation [15,17]. EBV gp350/220 is a viral glycoprotein, but the plasma membrane as well as the virus envelope is rich in it because the virus acquires its envelope at the plasma membrane [1].…”

“…We used a mouse monoclonal antibody called 72A1 to detect EBV-reactivated cells [15,17]. 72A1 is an antibody against gp350/220, a late protein of EBV reactivation.…”

“…The cultured PBMCs were introduced to conditions of 33 C to induce EBV reactivation [13][14][15], which was regarded as day 0. Every 5 days, half of the culture fluid was collected and replaced by fresh medium.…”

Epstein-Barr Virus Promotes Human Monocyte Survival and Maturation through a Paracrine Induction of IFN-α

“…mAb 72A1 specifically binds to the major viral envelope gp350 and has been previously shown to block the attachment of EBV to the EBV receptor CR2/CD21 on B cells (43). Prior treatment of EBV with anti-gp350 mAb reduced the virus-induced increase in monocyte viability by ϳ75% (Fig.…”